Why Attend
The world shut down in 2020 as the pandemic had a global impact on trade and development, but the onco cell therapy industry remained resilient in the face of all of this. In spite of 69% of industry claiming that their biggest challenges in 2020 was meeting their projected timelines for their pipes, the race for bringing the first BCMA targeting CAR-T to the market is reaching a climax and next-generation cell therapies are at the front of mind for those in both industry and research.
Significant break throughs in GvHD for allogeneic treatments and in the use of alternative cell therapies mean that onco cell therapies are embedding themselves as the 5th pillar of oncology. New combination studies and manufacturing capabilities are showing even more promise for this sector, but with current treatments still having high costs of use and as there are limited patient pools, there are still challenges in both clinical and commercial use of these therapies.
The Onco Cell Therapy Summit (OCTS), November 16 - 18, Boston USA, brings the industry together to share novel research, manufacturing techniques, and regulatory best practice. Each session of OCTS 2021 is dedicated to the process of translating R&D into commercially viable oncological therapies.
We’ve worked with industry partners to ensure that OCTS 2021 is dedicated to the effective translation and commercialization of research into safe and efficacious therapies and address these challenges.
TESTIMONIALS
Meet our 2021 Industry- Leading Speakers
Dr. Kristen Hege
Frank Fan
Paul Rennert
Tony Ho
Bruno Figueroa
Simon Bornschein
Dr. Maria Fardis
Dr. Maria Fardis joined Iovance Biotherapeutics as President and Chief Executive Officer and was appointed to the Board of Directors in 2016. Since joining, the Company has been transformed from an early-stage development company to a company with multiple late-stage programs involving lifileucel and LN-145 for treatment of multiple solid tumors. Dr. Fardis served as the Chief Operating Officer of Acerta Pharma B.V., a clinical-stage biopharmaceutical company, from January 2015 to March 2016, where she worked on the development of Calquence® until the company’s acquisition by AstraZeneca. From 2011 to 2014, she worked at Pharmacyclics, Inc., where she was a key contributor in the creation of a broad clinical program leading to global approvals for Imbruvica® in multiple hematologic malignancies, and where she served as Chief of Oncology Operations and Alliances. Prior to joining Pharmacyclics, from August 2001 to April 2011, Dr. Fardis held increasingly senior positions in Medicinal Chemistry and the project and portfolio management department at Gilead Sciences, Inc., where she was involved with multiple therapeutic areas including antivirals, oncology, and cardiovascular therapeutics and worked on the development and life cycle management of Letairis®. Dr. Fardis received her Ph.D. in Organic Chemistry from the University of California, Berkeley and her B.S. summa cum laude, in chemistry from the University of Illinois, Urbana-Champaign. Dr. Fardis holds an M.B.A., with highest honors, from Golden Gate University.
Pascal Touchon
Dr. Matthew Spear
Paul Lammers
James Trager
Robert Hofmeister
Gary Lee
Travis Young
Dan Shelly
Alice Brown
Hanspeter Gerber
Alan Trounson
Roman Yelensky
John Rossi
Adrian Bot
Dolores Schendel
Kristina Carroll
Kristina is a Process Engineer and founding member of the Cell Therapy Development team at Precision BioSciences, focused on the development of best-in-class manufacturing methods for allogeneic CAR T therapies. As an integral part of the CMC team, Kristina led in the development of the large-scale manufacturing process, cold chain logistics for the cryopreserved drug product, and clinical administration protocols. Prior to joining Precision BioSciences, Kristina worked as a Systems Engineer at Terumo BCT, focusing on upstream and downstream cell processing systems. She has earned her Master’s degree in Biomedical Engineering from Rutgers University and Bachelor’s degree in Chemical and Biological Engineering at the University of Colorado at Boulder. When not at Precision, Kristina can be found running nearby trails with her husband and dogs, camping, or creating a disaster in the kitchen.
Blake Aftab
Steven Kanner
Donna Rill
Krishnan Viswanadhan
Dr. Avery Posey
Frank Thielmann
Steven Feldman
Dr. Steven A. Feldman was a Staff Scientist and Director of the Vector Production Facility at Surgery Branch, NCI for the past twelve years. Dr. Feldman’s group was responsible for the development, characterization, and manufacturing of the viral vectors used in gene therapy clinical trials at the Surgery Branch. Recently, Dr. Feldman joined the Stanford Center for Cancer Cell Therapy as Director of Manufacturing and Process Science where he will take a lead role in the development and manufacture of viral vectors and novel cell therapies for the treatment of cancer.
Emilie Gauthy
Nick Huntington
Knut Niss
Dr. Niss has served as Chief Technology Officer since March 2018. Dr. Niss joined Mustang in March 2017 as Vice President of Operations, where he initiated and oversees the establishment of Mustang’s cell therapy manufacturing facility. Prior to Mustang, Dr. Niss was Cell Therapy Asset Leader at Biogen, where he oversaw CMC-related activities for gene-edited hematopoietic stem cell and lentiviral gene therapy programs for sickle cell disease and hemophilia, respectively. Earlier in his career, Dr. Niss was Senior Technical Project Leader at Novartis’ cell therapy manufacturing facility in Morris Plains, New Jersey, where he directed the transfer and implementation of the CTL019 process from Penn to Novartis. He also served as Senior R&D Program Manager at EMD Millipore, where he established processes for the large-scale expansion of adult and pluripotent stem cells. Dr. Niss began his career in senior research positions in Pfizer’s Regenerative Medicine and Immunology groups. He holds a Ph.D. in molecular biology from Humboldt University of Berlin, and an M.S. in microbiology from the University of Göttingen in Germany. Dr. Niss completed his postdoctoral research at Boston Children’s Hospital and the Dana-Farber Cancer Institute.
John Tomtishen
Anthony Colenberg
Chris Heery
Jason Litten
Tatiana Novobrantseva
Kipp Weiskopf
Judith Varner
Nicholas Poirier
Yaron Pereg
David Cheresh
Nico Lachmann
Michael Klichinsky
Ashish Kulkarni
Sandro Matosevic
Eric Von Hofe
Charles Mooney
Albert Ribickas
Bob Valamehr, PhD MBA,
Daniel Getts
Dean Lee
Frederick Locke Vice
Lawrence Lamb
Moa Fransson
Neehar Bhatia
Neehar Bhatia, Ph.D. is Associate Director of Process Development and Manufacturing at Laboratory of Cell and Gene Medicine (LCGM), Stanford University. Dr. Bhatia received a Ph.D. in Biochemistry from the Central Drug Research Institute, India. Dr. Bhatia is responsible for development and manufacturing of cGMP compliant cell and gene therapy products at LCGM. Dr. Bhatia oversees manufacturing for multiple projects such as CD19/CD22 bi-specific CAR-T and other T cell based therapies, CD34 HSPC transplant and manufacturing of AAV6 for gene correction in HSPC. Dr. Bhatia has lead multiple projects which include banking of ESCs, iPSCs, MSCs and iPSC derived differentiated cells, development of GMP process for translational projects and manufacturing cell therapies for Phase I/II clinical trials. Dr. Bhatia has also lead efforts in quest for serum-free chemically defined culture medium for MSCs and development of platform technology for AAV production. Dr. Bhatia’s focus is on development of cGMP compliant manufacturing process for “bench to bedside” cell and gene therapies.
Rafael Amado
Sheng Lin-Gibson
William Shingler
Charles Morris
WHO WILL BE THERE
Network with industry experts from:
- Big pharma and biotech
- Cell Therapy Academics and clinicians
- Process standardisation - technology/services
- Logistics companies - cell storage/transport
- Service providers - CRO’s, Consultants, Government
Past attendees include:
Sponsors
Platinum Partner
Miltenyi Biotec
Website: www.miltenyibiotec.com
At Miltenyi Biotec, we are committed to enabling the delivery of new cell and gene therapy (CGT) treatment options to patients with unmet medical needs. We develop tailored cell processing protocols for our GMP-compliant cell processing platform, the CliniMACS Prodigy®, to enable fully closed and automated manufacturing of complex CGT products. In addition, we offer contract development and GMP manufacturing of CGT products as well as design, development, and production of tailored GMP lentiviral vectors
Gold Partner
American Red Cross
Website: https://www.redcrossblood.org/biomedical-services/specialty-services/cell-and-gene-therapy-solutions.html
The Cell & Gene Therapy Solutions division of the American Red Cross is a nationwide leader in the provision of allogeneic and autologous collections for cell and gene therapy. Our products support a broad range of uses, from bench research to use in clinical trials and the manufacture of commercial therapies.
We currently perform autologous Mononuclear Cell collections at 62 Red Cross sites across the country and at multiple hospital locations. Our allogeneic Mononuclear Cell products are collected from healthy donors at five Red Cross sites across the country, and can be shipped fresh or frozen.
Our five full-service cellular therapy labs perform processing, freezing and storage of apheresis material. This, along with our ability to offer robust customization, allows us to both collect and process apheresis products according to our customers’ specifications and unique needs.
Lonza
Website: www.capsugel.com
Following the closing of the Capsugel acquisition, Lonza further strengthened its position as one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. Lonza harnesses science and technology to create products that support safer and healthier living and that enhance the overall quality of life.
Lonza Consumer Health & Nutrition combines expertise in high-quality, science-backed ingredients with formulation know-how and industry-leading capsule and encapsulation technologies to create innovative solutions for consumer health and nutrition companies. Our deep clinical knowledge supports specialty ingredients with proven performance, enabling customers to address consumer health concerns via new, differentiated health products.
We apply consumer market insights and our extensive experience in pharmaceutical delivery science to help our customers improve bioavailability, targeted delivery, swallowability, taste and odor masking of their nutritionals. Our technology enables unique combination products and provides visually appealing dosage forms that meet the expectations of today’s health-conscious consumers.
We also bring exceptional service capabilities, global regulatory expertise, and expert technical service to support our customers in quickly delivering differentiated nutritional products to market.
nanoString
Website: https://www.nanostring.com/
NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter® Analysis System, which has been employed in basic and translational research and cited in 1,000+ peer review publications, has also now been applied to diagnostic use with the nCounter Dx Analysis System. The company is committed to offering tools that enable scientists and clinicians to translate today’s leading genomic research into clinically actionable tests that improve patient care. Gene expression panels for immune- oncology, autoimmunity, CAR-T and other applications are ready off the shelf tools offered to the Nanostring customers.
ScaleReady
Website: www.scaleready.com
About Us
ScaleReady is a joint venture between Bio-Techne, Fresenius Kabi, and Wilson Wolf. Bringing together proven tools and technologies for cell culture, cell activation, gene editing, and cell processing, ScaleReady provides leading therapeutic developers with the most simple, scalable, and versatile manufacturing platform in the industry. Our platform includes G-Rex® cell culture technology, the Lovo and Cue cell processing systems, and a wide range of GMP proteins, reagents, media, and gene editing technologies.
Blood Centers of America
Website: http://bca.coop/
BCA is the nation’s largest blood supply network, providing over 50 percent of the nation’s blood supply. This national organization is comprised of over 60 independent community blood centers with a deep local commitment to the communities and patients they serve.
The BCA network encompasses over 500 collection and testing sites across the United States. In addition to meeting the transfusion needs of the communities they serve, BCA members provide human blood products, custom collections, cell processing, testing, storage, distribution and other services to the therapeutic, diagnostic and cell therapy industries. BCA members actively collect and provide critical raw materials for manufacturing of autologous and allogeneic cell-based therapies. Collectively BCA’s members interact with nearly three million individual blood donors annually.
In response to the COVID-19 pandemic, BCA optimized the collection of convalescent plasma donations from those recovered from COVID-19 (CCP). The donated blood is processed, and the plasma and antibodies are delivered intravenously to people actively battling the COVID-19 virus. BCA’s effort with CCP has been as a partner of Operation Warp Speed, which includes involvement with HHS, CDC, NIH, BARDA, DOD and other public agencies for the development of COVID-19 vaccine and therapeutic treatments.
APCER Life Sciences
Website: https://www.apcerls.com/
Together for Patient Safety
Patient safety has been and will always be the utmost priority for achieving high quality healthcare.
APCER Life Sciences is committed to provide assurance services to the pharmaceutical and biotech companies who are dedicated towards developing drugs, vaccines and advanced therapies for diseases and betterment of the society.
The ongoing public health crisis and life-threatening ailments like rare diseases require safer and effective therapies based on the benefit risk assessment. Our clients benefit from the medical and scientific knowledge which our team of experts bring forth by continuously monitoring scientific and regulatory developments globally thereby ensuring ‘Patient Safety’ with high quality treatments. Brexit has brought about changes in pharmacovigilance requirements for products authorized in the United Kingdom and Europe. We help provide consulting to the biopharma companies who want to market their products and face difficulties in getting market approvals in these regions. Our team of experts work together in mapping out cohesive solutions to help in smooth transitioning of processes.
About APCER Life Sciences
APCER Life Sciences provides comprehensive drug safety/pharmacovigilance, medical information, medical writing, regulatory services, quality assurance and risk management programs to pharmaceutical and biotech companies globally.
We bring medicinal / scientific expertise through our healthcare professionals & physicians and address end-end pharmacovigilance requirements for North America, UK & Europe markets. Our clients benefit from our vast experience in regulatory submissions across 100+ countries and consultative approach towards audit /inspection readiness.
Our focus towards Patient safety and Risk profile management makes us the preferred choice for pharma companies who are looking for pre /post marketing compliance & reporting solutions.
KBI Biopharma
Website: https://www.kbibiopharma.com/
KBI Biopharma, Inc. is a biopharmaceutical Contract Development and Manufacturing Organization that accelerates the development of innovative discoveries into life-changing biological products. From early-stage to academic/non-profit organizations, to many of the world’s largest pharmaceutical companies, KBI has served 250+ clients globally to accelerate and optimize their drug development programs.
KBI’s extensive track record of successful programs is a result of its unique approach: applying the insight gained from our advanced biophysical and analytical characterization techniques toward the development of robust and scalable processes. KBI delivers accelerated and integrated process development and cGMP manufacturing programs for a wide range of recombinant protein Active Pharmaceutical Ingredients (API) and cell therapy products for our clients. KBI was founded in 1996 and operates 3 manufacturing facilities: Durham (NC), Boulder (CO), and The Woodlands (TX).
Event Partner
Berkley Lights
Website: https://www.berkeleylights.com/
OUR MISSION
We find the best cells.
Discovery of cellular therapies, biopharmaceuticals, and other cell-based products depends on precise, time-consuming, cell-by-cell manipulations. But biologists need to move faster and more efficiently to meet today’s scientific demands. Our mission is to accelerate the use of cell-based products by providing researchers access to the Berkeley Lights Platform to find the best cells in a fraction of the time and at a fraction of the cost of traditional methods.
Myriade
Website: http://www.myriadelab.com/en/
Myriade is a French company created in 2017 that develops an innovative nanoscale imaging technology: the VIDEODROP
Based on the principles of interferometry, the Videodrop makes it possible to visualize living nanoparticles in the range of 30 nm and 10 microns without labeling, in real time and in a single drop.
The Videodrop processing algorithms compute the concentration and size distribution of the nanoparticles and enable to analyze complex mixtures of phages (T4, lambda) for applications in phagotherapy, continuously monitor viral vector solutions (Lentiviruses, adenoviruses) for gene and cell therapy, and distinguish the different types of EVs to vectorize, diagnose or treat
PeproTech
Website: www.peprotech.com
Established in 1988 by a group of scientists, PeproTech is a privately owned biotechnology company focusing on the development and manufacture of high quality cytokine products for the life-science and cell therapy markets. Over the past 30 years the company has grown into a global enterprise with state-of-the-art manufacturing facilities in the US, and offices around the world.
With over 2,000 products PeproTech has developed and refined innovative protocols to ensure quality, reliability and consistency.
Our mission is to provide the highest quality products to support the needs of today’s scientists and researchers.
Please contact: 800-436-9910 or [email protected]
Sexton Biotechnologies
Website: www.sextonbio.com
Sexton Biotechnologies is a company focused on the development and sales of bioproduction tools for cell and gene therapy founded in 2019, located in Indianapolis, IN. Sexton develops purpose-built CGT tools and media to enable flexible automation and scaling of cell manufacturing processes to increase the probability of positive clinical outcomes and reduce time-to-market, failure points, and labor costs. Sexton's portfolio includes the CellSeal platform of cryo-storage tools and fill/finish systems and human platelet lysate growth supplements.
Biocytogen
Website: https://biocytogen.com/
Biocytogen offers a full suite of integrated services to advance therapeutic discovery and development for customers in the biotech and pharmaceutical industries, using state-of-the-art technologies for single cell antibody discovery, gene editing, and a large supply of animal disease models. Biocytogen’s in vivo pharmacology services support efficacy testing of antibody therapeutics, small molecules, and CAR-T therapy, using custom humanized mice expressing knocked-in human targets, wild-type mice, or severely immunodeficient (B-NDG) mice. Biocytogen collaborates with global partners to accelerate the discovery and development of novel therapeutics for oncology, immuno-oncology, autoimmune diseases, and other inflammatory diseases.
For more information, please visit www.biocytogen.com.
CTI
Website: https://www.ctifacts.com/
From a small team in an old carriage house to associates in more than 60 countries across the world.
We have now worked on more than 6000 projects, worked on every continent except Antarctica, and have contributed to more than 130 new drug and device approvals through global regulatory agencies such as the FDA, EMA, and others. Currently, we work with more than 200 pharmaceutical and emerging biotechnology and medical device companies.
VIVEbiotech
Website: https://www.vivebiotech.com/
VIVEbiotech is a GMP CDMO fully focused on the development and GMP manufacture of lentiviral vectors from very early stages (even scratch) to GMP.
Being fully focused on customers´ projects, VIVEbiotech adapts to their requirements being highly flexible in terms of technical adaptation and slots availability.
VIVEbiotech is currently working for clients based in Europe, USA and Asia, manufacturing lentiviral vectors for different applications such as rare diseases as well as immune-oncology (CAR-Ts, TCRs, CAR-NKs, TILs), among others.
One of VIVEbiotech´s main features is our specialization in virology. Based on it, our R&D department is focusing its efforts on the development of more cost-effective processes and safer lentiviral vectors (worldwide patented technology called Lentisoma).
Media Partners
CheckRare
Website: https://checkrare.com/
CheckRare is a learning platform for health care professionals and patients. Our platform allows users to gain insight and learn about rare diseases, current and emerging therapies, clinical trials, and the BioPharma companies behind them. Our peer-to-peer content is a trusted source for education and industry-related content. Our native content and sponsored programs are developed through our website, e-newsletter, social media platforms, and live meetings. We are a trusted, strategic partner with all major organizations in the global network of rare disease advisors and advocates. There is no fee to register on CheckRare and all content is free of charge.
Gene Therapy Net
Website: www.genetherapynet.com
Gene Therapy Net is the information resource for basic and clinical research in gene therapy, and the site serves as a network in the exchange of gene therapy information and breaking news items. Visitors can keep track of the latest scientific papers, conference announcements, gene therapy jobs, regulations and guidelines.
World Pharma Today
Website: https://www.worldpharmatoday.com/
Please visit our website for more information.FierceBiotech
Website: www.fiercebiotech.com
Read the latest biotechnology articles on biotech industry leaders, emerging biotech companies, FDA decisions, VC deals, and other biotech industry news.
FierceBiotech and its family of publications provide end-to-end coverage of biotech and medtech, from pre-clinical science through clinical testing and regulatory approval—and all the seed funding, venture capital, licensing deals, IPOs and M&A that happen along the way.
We track tiny, virtual startups and the biggest of Big Pharma, highlighting the accomplishments and acknowledging the defeats that all of them experience on their way to market with a new therapy or device.
The FierceBiotech team transcends the daily as well, with comprehensive coverage of key medical meetings plus special reports that highlight up-and-comers and shed new light on industry heavyweights.
Pharma Journalist
Website: www.pharmajournalist.com
Pharma Journalist is a leading international B2B magazine providing the global information and the recent updates in the Pharmaceutical Industry.
Our editorial staff works dedicatedly to provide latest information of Pharmaceutical Industry in the form of articles, news, trends, analysis, market report, press releases, whitepapers, case studies, etc. which helps Industry professionals and decision makers to stay on the top of this fast-paced industry.
Various Online marketing services and promotional activities through Pharma Journalist helps companies and organizations to reach their target audience and create brand awareness.
PARTNER WITH US
Based on your objectives, we can create bespoke packages designed specifically for you. From presenting your expertize on the main stage to hosting the infamous CAR-T Party. You can partner with us showcase your brand and make valuable new connections. Opportunities predominantly lie in 3 main categories: Thought Leadership, Branding & Networking. Contact Take a look at the Sponsorship Prospectus for more details, or discuss your objectives with Nathan Edwards, Head of Commercial Partnerships; [email protected].
Interested in a media partnership?
We'd love to hear from you and how we can support one another to connect with the industry. Contact Sarah Rowlands, Marketing Director; sarah.rowlands[@]kisacoresearch.com.
Sending Your Team? Group Discounts Available!
Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates
Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off
If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920
Ticket price will increase in
Terms & Conditions
In the event that Kisaco Research postpones an event for any reason or changes the event format to ‘virtual event’, any in-person registrations for this event will be automatically transferred to the virtual registration package. The delegate will receive a credit note for the difference in ticket value from the fee paid. You may use this credit for another Kisaco Research event to be mutually agreed with Kisaco Research, which must occur within 12 months from the date of the event which the delegate had originally registered for.
Agenda
You can download our latest agenda here.
Download the 2021 agenda now. Simply fill in this form and we'll send you a PDF version immediately. We need some information to know where to send the file and how to address our email to you.
Download 2021 Agenda
Venue
Boston Park Plaza, 50 Park Plaza, Boston, MA 02116, United States
Boston Park Plaza, 50 Park Plaza, Boston, MA 02116, United States
There are a limited number of rooms at $199 per night. Rate can be used for nights between 15th to 18th November. Click here to book.
Returning Safely Measures
Whether sponsors, speakers or attendees, our customers attend Kisaco Research events to connect, learn and innovate to know more and do business. It is our commitment that as we return to in-person events, they can do this effectively, safely and with confidence.
All in-person Kisaco Research events will prioritize the health and safety of colleagues and customers and, in the first instance, will be run in accordance with official government and local authority guidance, as well as any venue or location-specific regulations.
Kisaco Research is committed to following the Association of Event Organisers All Secure Standard, which has been approved by by UK Government.
About Kisaco Research
Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.
Meet industry peers that will help build a career-changing network for life.
Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.
Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.
Invest both in your company growth and your own personal development by signing up to one of our events and get started.